1. Home
  2. UTG vs MLYS Comparison

UTG vs MLYS Comparison

Compare UTG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UTG

Reaves Utility Income Fund of Beneficial Interest

HOLD

Current Price

$37.08

Market Cap

3.3B

Sector

Finance

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$36.73

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UTG
MLYS
Founded
2003
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
UTG
MLYS
Price
$37.08
$36.73
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$46.40
AVG Volume (30 Days)
317.8K
1.8M
Earning Date
01-01-0001
11-10-2025
Dividend Yield
7.28%
N/A
EPS Growth
N/A
N/A
EPS
9.86
N/A
Revenue
$96,107,593.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.20
N/A
Revenue Growth
8.35
N/A
52 Week Low
$25.26
$8.24
52 Week High
$35.29
$47.65

Technical Indicators

Market Signals
Indicator
UTG
MLYS
Relative Strength Index (RSI) 43.82 37.94
Support Level $37.04 $37.61
Resistance Level $38.00 $44.13
Average True Range (ATR) 0.71 2.05
MACD 0.06 -0.71
Stochastic Oscillator 46.75 2.72

Price Performance

Historical Comparison
UTG
MLYS

About UTG Reaves Utility Income Fund of Beneficial Interest

Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: